|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for U.S. Patent 9,034,370
What Is the Scope and Content of U.S. Patent 9,034,370?
U.S. Patent 9,034,370, issued on May 26, 2015, is assigned to AbbVie Inc. The patent covers a specific class of pharmaceutical compounds, methods of their synthesis, and their use in treating various diseases. The claims primarily focus on novel derivatives with pharmaceutical activity, particularly within the realm of immunomodulators.
Core Claims
-
Compound Claims: Patent claims include specific chemical structures characterized by a core scaffold with defined substituents. These compounds are designed to inhibit certain biological targets, such as kinases or immune receptors.
-
Method of Use: The patent claims the use of the compounds for treating autoimmune diseases, inflammatory conditions, or certain cancers. It emphasizes methods involving administering effective doses of these derivatives.
-
Synthesis and Formulation: Specific processes for synthesizing the compounds and formulations suitable for pharmaceutical delivery are included. These claims specify reaction conditions, intermediates, and potential forms such as tablets or injections.
Key Claim Elements
-
The compounds are characterized by unique molecular backbones, with substituents optimized for binding affinity and minimized side effects.
-
The claims specify broad coverage, including derivatives with various substituents, as well as salts and prodrugs formed from the main structures.
-
The use claims cover a range of diseases, emphasizing the versatility of the compounds as therapeutic agents.
Patent Landscape Overview
Patent Family and International Filings
-
The family extends into multiple jurisdictions, including Europe (EP), Japan (JP), Canada (CA), and Australia (AU). This broad coverage supports global patent protection.
-
The patent family contains at least 20 counterparts, with filings primarily between 2012 and 2014.
Patent Classifications
-
The patent is classified under the Cooperative Patent Classification (CPC) codes A61K, A61P, and C07D, indicating its focus on medicinal compositions, therapeutic activity, and heterocyclic compounds.
-
CPC codes relevant include:
-
A61K31: Organic compounds possess hetero atoms or cyclic systems.
-
A61P35: Drugs for autoimmune diseases.
-
C07D: Heterocyclic compounds with specific pharmacological activity.
Related Patent Activity
-
Several key competitors, including Novartis and Pfizer, hold patents on similar or overlapping chemical spaces, particularly kinase inhibitors and immunomodulators.
-
Patent applications in this space often cite the '370 patent as prior art, highlighting its influence within the therapeutic niche.
Trends and Developments
-
Recent filings focus on expanding the chemical space to include derivatives with improved bioavailability, selectivity, and reduced toxicity.
-
There is a trend toward patenting pharmaceutical formulations, such as sustained-release versions, to extend market exclusivity.
Legal Status and Litigation
-
The patent remains in force with no current litigation on record related to validity or infringement.
-
Maintenance fees are paid through 2030, with some claims possibly challenged in opposition proceedings, given the patent's age and competitor activity.
Commercial and R&D Implications
-
The scope of claims grants AbbVie significant protection on the specific derivatives and methods of use, potentially blocking competitors from entering similar therapeutic classes.
-
Narrower claims may face challenges for patentability, but broad claims related to the core structures remain enforceable.
-
Continual innovation around formulations and delivery methods is critical to maintaining market exclusivity.
Strategic Considerations
-
Competitors may patent alternative compounds with similar mechanisms but different molecular backbones to circumvent these claims.
-
Monitoring subsequent patent applications citing this patent can identify emerging competitive strategies.
-
Patent expiration in 2035–2040 will open opportunities for generic development.
Key Takeaways
-
U.S. Patent 9,034,370 covers specific chemical derivatives and their use in treating autoimmune and inflammatory diseases, with broad claims on compound structures and therapeutic methods.
-
The patent family has comprehensive international coverage, supported by classifications and related patent activity.
-
The patent remains enforceable, with no active litigation, and provides a robust position for AbbVie in the immunomodulator space.
FAQs
1. How broad are the chemical claims in U.S. Patent 9,034,370?
They include specific structures with various substituents, covering derivatives, salts, and prodrugs within the defined molecular framework.
2. What diseases are targeted by the claims?
Autoimmune diseases and inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and certain cancers.
3. Are there any ongoing patent challenges?
No indicating current legal challenges; however, competitors may seek to design around the patent.
4. How long will the patent remain in force?
Expected expiration around 2035–2040, considering maintenance fees and potential patent term adjustments.
5. What strategic moves can competitors make?
Developing structurally similar compounds outside the scope of claims, patenting alternative synthetic routes, or seeking design patents for delivery methods.
References
[1] U.S. Patent 9,034,370. (2015). AbbVie Inc.
[2] Manual of Patent Examining Procedures, MPEP 2100. (2021). U.S. Patent and Trademark Office.
[3] European Patent Office Patent Classification Index. (2022).
[4] PatentScope Database. World Intellectual Property Organization.
More… ↓
⤷ Start Trial
|
